PACIRA BIOSCIENCES: BARCLAYS LOWERS TARGET PRICE FROM $27 TO $25

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: Mar 26 2026

0mins

PCRX-1.77%

Should l Buy PCRX?

Source: moomoo

Barclays Adjusts Price Target: Barclays has reduced its price target for a specific stock from $27 to $25.
Market Implications: This adjustment may reflect changing market conditions or company performance expectations.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PCRX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PCRX

Wall Street analysts forecast PCRX stock price to rise

6 Analyst Rating

4 Buy

1 Hold

1 Sell

Moderate Buy

Current: 23.150

Low

23.00

Averages

30.33

High

38.00

Current: 23.150

Low

23.00

Averages

30.33

High

38.00

Needham

Buy

maintain

$30 -> $32

2026-05-01

Reason

Needham

Price Target

$30 -> $32

AI Analysis

2026-05-01

maintain

Buy

Reason

Needham raised the firm's price target on Pacira to $32 from $30 and keeps a Buy rating on the shares after its Q1 earnings beat. The company's Q1 volume was up 7%, in line with growth seen in 2025, as it continues to expect similar volume growth and improved pricing dynamics once final GPO contract lapses in the middle of this year, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$38

2026-04-13

Reason

H.C. Wainwright

Price Target

$38

2026-04-13

maintain

Buy

Reason

H.C. Wainwright says the real-world data on Exparel indicate it can lead to lower or comparable total healthcare costs and reduced opioid usage. Pacira presented real-world data supporting the payer value proposition of liposomal bupivacaine, the analyst tells investors in a research note. The firm believes the strength of the evidence appears to depend on the specific procedure, with a more compelling economic signal observed in total hip arthroplasty compared to total knee arthroplasty. While the data in total hip arthroplasty pointed to meaningful cost savings, the total knee arthroplasty data points to cost parity, though that doesn't fully capture clinical benefits or patient satisfaction benefits that use of Exparel may provide, contends H.C. Wainwright. The firm believes the data highlights a reduction in opioid usage at six months post-surgery among patients with low back pain who underwent total hip arthroplasty. It keeps a Buy rating on Pacira with a $38 price target. The stock in midday trading is up 1% to $24.11.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PCRX

Unlock Now

About PCRX

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Pacira BioSciences CFO Sells Shares for $326,000

May 01 2026Fool

Insider Stock Transaction: On April 23, Pacira BioSciences CFO Shawn Cross exercised 12,941 stock options and immediately sold them for approximately $326,000, indicating a pre-planned liquidity strategy.
Ownership Change: Following the sale, Cross's direct stock holdings decreased by 10.94%, leaving him with 105,341 shares valued at around $2.67 million, suggesting he maintains a significant ownership stake.
Market Performance: Despite a modest 0.63% increase in Pacira's stock price over the past year, the stock experienced over a 20% decline at one point in 2026, highlighting its volatility and the need for investors to monitor future financial results closely.
Product Line Expansion: Pacira generates revenue primarily from non-opioid pain management products, and management emphasized that the upcoming completion of the phase 3 registrational study for Zilretta could present a significant new market opportunity, further driving revenue growth.

Pacira CFO Sells Shares to Enhance Liquidity

May 01 2026NASDAQ.COM

Executive Stock Transaction: On April 23, 2026, Pacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares of common stock for approximately $326,000 at $25.16 per share, indicating a focus on enhancing liquidity.
Change in Holdings: This transaction represented 10.94% of Shawn Cross's direct common stock holdings, while he retains 150,000 stock options, supporting future liquidity capacity despite the sale.
Financial Performance Highlights: Pacira reported total revenue of $177 million for Q1 2026, a 5% year-over-year increase that exceeded analyst expectations, reflecting sustained demand in the non-opioid pain management market.
Market Volatility: Despite a modest 0.63% price change over the past year, Pacira's stock experienced a decline of over 20% at one point in 2026, highlighting the market's keen interest in the company's future developments and clinical trial outcomes.

Pacira BioSciences Q1 2026 Earnings Call Insights

May 01 2026seekingalpha

Sales Momentum: Pacira BioSciences reported Q1 EXPAREL net sales of $143.3 million, up from $136.5 million in 2025, despite winter storm disruptions, indicating strong market performance with approximately 7% volume growth.
R&D Progress: Enrollment for a Phase III registrational study in shoulder osteoarthritis has concluded, with top-line results expected later this year, further enhancing the company's innovation and competitive edge in pain management.
Financial Outlook: The company reiterated its 2026 total revenue guidance of $745 million to $770 million, with EXPAREL net product sales projected between $600 million and $620 million, reflecting confidence in future growth and clarity in strategic planning.
Share Repurchase Program: In Q1, the company executed $50 million in share repurchases, retiring approximately 2.2 million shares of common stock, which enhances shareholder value and demonstrates confidence in its financial health.

Pacira BioSciences Q1 Earnings Exceed Expectations

Apr 30 2026seekingalpha

Earnings Beat: Pacira BioSciences reported a Q1 non-GAAP EPS of $0.60, exceeding expectations by $0.04, indicating a robust profitability trend that may attract further investor interest.
Revenue Growth: The company achieved $177 million in revenue for Q1, reflecting a 4.8% year-over-year increase and surpassing expectations by $3.66 million, demonstrating stable product demand and promising future growth potential.
Share Repurchase Program: Pacira repurchased 2.2 million shares of common stock at an average price of $22.28 per share, costing $50 million, which not only enhances EPS but also reflects the company's confidence in its intrinsic value.
2026 Revenue Target: The company outlined a revenue target of $745 million to $770 million for 2026, leveraging its 5x30 strategy to drive margin improvements and pipeline progress, indicating a positive outlook for future growth.

PharmaCorp to Present at 2026 Healthcare Investor Conference

Apr 02 2026Yahoo Finance

Conference Participation: PharmaCorp Rx Inc. will deliver a corporate presentation at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, at 9:30 AM ET in Toronto, showcasing its latest developments in Canadian pharmacy services to attract investor interest in its business model and market potential.
One-on-One Meeting Opportunities: Senior management will engage in one-on-one meetings during the conference, providing direct interaction opportunities with potential investors, thereby enhancing trust and interest in PharmaCorp and facilitating future capital collaborations.
Industry Context: The Bloom Burton & Co. Healthcare Investor Conference gathers American, Canadian, and international investors focused on the latest developments in the Canadian healthcare sector, and PharmaCorp's participation will help elevate its visibility and influence within the industry.
Strategic Goals: PharmaCorp aims to build a national network of community pharmacies by acquiring and supporting succession plans for pharmacy owners, currently operating seven PharmaChoice Canada bannered pharmacies, with plans to continue expanding its market share and enhancing competitiveness.